EDMONTON, Alberta, Nov. 1 /PRNewswire-FirstCall/ -- Medical Services International Inc is pleased to announce that it has received independent test results from a major regulatory agency related to its VScan TB test kit showing that it is the most reliable test available. Of the 19 tests used in the study, 7 received a rating of most reliable. The VScan TB test was one of the seven. In addition to the most reliable rating, the VScan TB test had a specificity of 95%. This was the highest of all the other tests considered most reliable. The highest that any other test kit achieved was a specificity of < 72%. The VScan TB test kit is the only test that does not give false positives.
The Company has had significant interest in its VScan TB test kit. As a result of this study, it is expected that the interest will increase significantly impacting VScan sales.
Regulatory agencies estimate that the number of new TB cases to be 8.8 worldwide annually. It is projected that this number will increase to over 10 million worldwide despite the implementation of a global strategy for diagnosing and treating TB in over 182 countries.
Simple, accurate, inexpensive Point of care diagnostic tools for TB are urgently needed.
The Company feels that its VScan TB rapid test kit will fill this demand.
Medical Services International Inc trades in the United States on the NQB Pink Sheets under the symbol “MSITF”. For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com or http://www.minerva-biotech.com.
NOTE: Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
CONTACT: Robert Talbot of Medical Services International, +1-780-430-6363
Web site: http://www.medicalservicesintl.com/
http://www.minerva-biotech.com/
